Parkinson's Disease, Review Article
Lancet 335:948-952, Marsden,C.D., 1990
Magnetic Resonance Imaging in Parkinson's Disease
Arch Neurol 47:735-737, Huber,S.J.,et al, 1990
Clozapine in the Treatment of Parkinsonian Patients with Dopaminomimetic Psychosis
Neurol 40:832-834, Wolters,E.Ch.,et al, 1990
Decreased Efficacy of Levodopa with Carbidopa in Parkinsonian Patients after Adrenal-to-Caudate Implants
Neurol 40:845-846, Tsui,J.K.C.,et al, 1990
Parkinson's Disease and Driving Ability
JNNP 53:580-582, Madeley,P.,et al, 1990
Clinical Diagnosis of Binswanger's Disease
JNNP 53:961-965, Bennett,D.A.,et al, 1990
Nasogastric and Intravenous Infusions of (+) -4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's Disease
JNNP 53:102-105, 1990, Coleman,R.J.,et al, 1990
Extrapyramidal Involvement in Rett's Syndrome
Neurol 40:293-295, FitzGerald,P.M.,et al, 1990
A Comparison of Effects of Controlled-Release Levodopa (Madopar CR) with Levodopa in Late Parkinson's Disease
JNNP 53:220-223, MacMahon,D.G.,et al, 1990
PET Study in Progressive Supranuclear Palsy, Hypometabolic Pattern
Arch Neurol 47:747-752, Blin,J.,et al, 1990
Cortical-Basal Ganglionic Degeneration
Neurol 40:1203-1212, Riley,D.E.,et al, 1990
Striatonigral Degeneration:Clinical, MRI, & Pathologic Correlation
Neurol 40:710-711, O'Brien,C.,et al, 1990
2-Amino-3- (methylamino) -Propanoic Acid (BMAA) in Cycad Flour:An Unlikely Cause of ALS & Parkinsonism-Dementia of Guam
Neurol 40:767-772, Duncan,M.W.,et al, 1990
Sustained Enteral Administration of Levodopa Increases and Interrupted Infusion Decreases Levodopa Dose Requirements
Neurol 40:995-997, Cedarbaum,J.M.,et al, 1990
Apomorphine Test to Predict Dopaminergic Responsiveness in Parkinsonian Syndromes
Lancet 336:32-34, Hughes,A.J.,et al, 1990
Two Decades of Increasing Mortality from Parkinson's Disease Among the US Elderly
Arch Neurol 47:731-734, Lilienfeld,D.E.,et al, 1990
Environmental Risk Factors in Parkinson's Disease
Neurol 40:1218-1221, Koller,W.,et al, 1990
Pyramid Sale in the Bucket Shop:DATATOP Bottoms Out
Neurol 40:1337-1339, Landau,W.M., 1990
Mortality Associated with Early and Late Levodopa Therapy Initiation in Parkinson's Disease
Neurol 40:265-269, Scigliano,G.,et al, 1990
Dopa-Responsive Dystonia:The Spectrum of Clinical Manifestations in a Large North American Family
Neurol 40:66-69, Nygaard,T.G.,et al, 1990
Subcutaneous Apomorphine in the Treatment of Parkinson's Disease
JNNP 53:96-101, Frankel,J.P.,et al, 1990
A Large Kindred with Autosomal Dominant Parkinson's Disease
Ann Neurol 27:276-282, Golbe,L.I.,et al, 1990
The Changing Patterns of Death Rates in Parkinsonism
Neurol 40:42-49, Kurtzke,J.F.&Murphy,F.M., 1990
Cognitive Change Following MPTP Exposure
Neurol 40:261-264, Stern,Y.,et al, 1990
Movement Disorders in Alcoholism:A Review
Neurol 40:741-746, Neiman,J.,et al, 1990
A Brain Transplant that Works
Lancet 335:445-446, , 1990
Medical Applications of Fetal Tissue Transplantation
Council Report, JAMA 263:565-5701990., , 1990
Adrenal Medullary Transplant to the Striatum of Patients with Advanced Parkinson's Disease
Neurol 40:273-276, Goetz,C.G.,et al, 1990
The Modern Management of Parkinson's Disease, Editorial
JNNP 53:93-95, Quinn,N., 1990
Stroke and Its Modification in Parkinson's Disease
Stroke 21:1395-1399, Struck,L.K.,et al, 1990
Driving and Parkinson's Disease
Editorial, Lancet 336:7811990., , 1990
Stereotaxic Thalamotomy-Experiences from the Levodopa Era
JNNP 53:427-430, Wester,K.&Hauglie-Hanssen,E., 1990
Temporal Arteritis Presenting as an Extrapyramidal Disorder
ActaNeurolScand 81:361-362, Santambrogio,L.,et al, 1990
Hypoxic-Ischemic Damage of the Basal Ganglia
Mov Disord 5:219-224, Hawker, K. & Lang, A.E., 1990
Antecollis in Parkinsonism
Lancet 1:1320-1321, Jorens,P.G.,et al, 1989
Magnetic Resonance Imaging in Parkinson's Syndromes
Neurol 39:1524-1526, Stern,M.B.,et al, 1989
Magnetic Resonance Imaging in Dementia of Parkinson's Disease
JNNP 52:1221-1227, Huber,S.J.,et al, 1989
Extrapyramidal Features in Central Lyme Borreliosis
Eur Neurol 29:150-155, Kohlhepp,W.,et al, 1989
Chronic Manganese Intoxication
Arch Neurol 46:1104-1106, Huang,C.C.,et al, 1989
Gerstmann-Straussler-Scheinker Disease, I, Extending the Clinical Spectrum
Neurol 39:1446-1452, Farlow,M.R.,et al, 1989
Selegiline Use to Prevent Progression of Parkinson's Disease
Arch Neurol 46:1275-1279, Elizan,T.S.,et al, 1989
Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group, NEJM 321:1364-13711989., , 1989
DATATOP:A Multicenter Controlled Clinical Trial in Early Parkinson's Disease
Parkinson Study Group, Arch Neurol 46:1052-10601989., , 1989
Selegiline as an Adjunct to Conventional Levodopa Therapy in Parkinson's Disease
Arch Neurol 46:1280-1283, Elizan,T.S.,et al, 1989
Swallowing Abnormalities and Their Response to Treatment in Parkinson's Disease
Neurol 39:1309-1314, Bushman,M.,et al, 1989
Cyanide-Induced Parkinsonism:Clinical, MRI, and 6-Fluorodopa PET Studies
Neurol 39:142-144, Rosenberg,N.L.,et al, 1989
Bromocriptine in Parkinson's Disease:A Double-Blind Study Comparing"Low-Slow"and"High-Fast"in de Novo Patients
UK Bromocriptine Res Group, JNNP 52:77-821989., , 1989
Cortical Lewy Body Dementia:Clinical Features and Classification
JNNP 52:185-192, Gibb,W.R.G.,et al, 1989
Dose-Dependent Memory Impairment in Parkinson's Disease
Neurol 39:438-440, Huber,S.J.,et al, 1989
Controlled Release of Dopamine from a Polymeric Brain Implant:In Vivo Characterization
Ann Neurol 25:351-356, During,M.J.,et al, 1989